Autor: "Lux, Michael P." - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
Autorzy:: Morra A; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Schreurs MAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Andrulis IL; Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Anton-Culver H; Department of Medicine, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, California, USA.
Augustinsson A; Oncology, Clinical Sciences in Lund, Lund University, Lund, Sweden.
Beckmann MW; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
Behrens S; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Bojesen SE; Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Bolla MK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Brauch H; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.; iFIT-Cluster of Excellence, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK), Partner Site Tübingen, German Cancer Research Center (DKFZ), Tübingen, Germany.
Broeks A; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Buys SS; Department of Internal Medicine and Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Camp NJ; Department of Internal Medicine and Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Castelao JE; Oncology and Genetics Unit, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Xerencia de Xestion Integrada de Vigo-SERGAS, Vigo, Spain.
Cessna MH; Intermountain Healthcare, Salt Lake City, Utah, USA.
Chang-Claude J; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Chung WK; Departments of Pediatrics and Medicine, Columbia University, New York, New York, USA.
Colonna SV; Department of Internal Medicine and Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Couch FJ; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Cox A; Department of Oncology and Metabolism, Sheffield Institute for Nucleic Acids (SInFoNiA), University of Sheffield, Sheffield, UK.
Cross SS; Department of Neuroscience, Academic Unit of Pathology, University of Sheffield, Sheffield, UK.
Czene K; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Daly MB; Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Dennis J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Devilee P; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.; Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Dörk T; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
Dunning AM; Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
Dwek M; School of Life Sciences, University of Westminster, London, UK.
Easton DF; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.; Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
Eccles DM; Faculty of Medicine, University of Southampton, Southampton, UK.
Eriksson M; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Evans DG; Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.; North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
Fasching PA; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
Fehm TN; Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
Figueroa JD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.; Cancer Research UK Edinburgh Centre, The University of Edinburgh, Edinburgh, UK.; Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Flyger H; Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
Gabrielson M; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Gago-Dominguez M; Cancer Genetics and Epidemiology Group, SERGAS, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) Foundation, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.
García-Closas M; Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
García-Sáenz JA; Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Genkinger J; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA.; Herbert Irving Comprehensive Cancer Center, New York, New York, USA.
Grassmann F; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.; Health and Medical University, Potsdam, Germany.
Gündert M; Molecular Epidemiology Group, C080, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Molecular Biology of Breast Cancer, University Womens Clinic Heidelberg, University of Heidelberg, Heidelberg, Germany.; Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
Hahnen E; Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Haiman CA; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Hamann U; Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Harrington PA; Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
Hartikainen JM; Translational Cancer Research Area, University of Eastern Finland, Kuopio, Finland.; Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland.
Hoppe R; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.; University of Tübingen, Tübingen, Germany.
Hopper JL; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
Houlston RS; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Howell A; Division of Cancer Sciences, University of Manchester, Manchester, UK.
Jakubowska A; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.; Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland.
Janni W; Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
Jernström H; Oncology, Clinical Sciences in Lund, Lund University, Lund, Sweden.
John EM; Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California, USA.; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA.
Johnson N; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Jones ME; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Kristensen VN; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway.
Kurian AW; Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California, USA.; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA.
Lambrechts D; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.; VIB Center for Cancer Biology, VIB, Leuven, Belgium.
Le Marchand L; Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Lindblom A; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.; Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.
Lubiński J; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Lux MP; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
Mannermaa A; Translational Cancer Research Area, University of Eastern Finland, Kuopio, Finland.; Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland.; Biobank of Eastern Finland, Kuopio University Hospital, Kuopio, Finland.
Mavroudis D; Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Greece.
Mulligan AM; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.; Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada.
Muranen TA; Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Nevanlinna H; Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Nevelsteen I; Department of Oncology, Leuven Multidisciplinary Breast Center, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.
Neven P; Department of Oncology, Leuven Multidisciplinary Breast Center, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.
Newman WG; Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.; North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
Obi N; Institute for Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Offit K; Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Olshan AF; Department of Epidemiology, Gillings School of Global Public Health and UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Park-Simon TW; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
Patel AV; Department of Population Science, American Cancer Society, Atlanta, Georgia, USA.
Peterlongo P; IFOM ETS - The AIRC Institute of Molecular Oncology, Genome Diagnostics Program, Milan, Italy.
Phillips KA; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
Plaseska-Karanfilska D; Research Centre for Genetic Engineering and Biotechnology 'Georgi D. Efremov', MASA, Skopje, Republic of North Macedonia.
Polley EC; Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Presneau N; School of Life Sciences, University of Westminster, London, UK.
Pylkäs K; Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland.; Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory Centre Oulu, Oulu, Finland.
Rack B; Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
Radice P; Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 'Predictive Medicine: Molecular Bases of Genetic Risk', Milan, Italy.
Rashid MU; Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Basic Sciences, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan.
Rhenius V; Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
Robson M; Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Romero A; Medical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Saloustros E; Department of Oncology, University Hospital of Larissa, Larissa, Greece.
Sawyer EJ; School of Cancer & Pharmaceutical Sciences, Comprehensive Cancer Centre, Guy's Campus, King's College London, London, UK.
Schmutzler RK; Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Schuetze S; Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
Scott C; Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Shah M; Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
Smichkoska S; Medical Faculty, University Clinic of Radiotherapy and Oncology, Ss. Cyril and Methodius University in Skopje, Skopje, Republic of North Macedonia.
Southey MC; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.; Department of Clinical Pathology, The University of Melbourne, Melbourne, Victoria, Australia.; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
Tapper WJ; Faculty of Medicine, University of Southampton, Southampton, UK.
Teras LR; Department of Population Science, American Cancer Society, Atlanta, Georgia, USA.
Tollenaar RAEM; Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
Tomczyk K; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Tomlinson I; Cancer Research Centre, The University of Edinburgh, Edinburgh, UK.
Troester MA; Department of Epidemiology, Gillings School of Global Public Health and UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Vachon CM; Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
van Veen EM; Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.; North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
Wang Q; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Wendt C; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.; Department of Oncology, Södersjukhuset, Stockholm, Sweden.
Wildiers H; Department of Oncology, Leuven Multidisciplinary Breast Center, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.
Winqvist R; Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland.; Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory Centre Oulu, Oulu, Finland.
Ziogas A; Department of Medicine, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, California, USA.
Hall P; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.; Department of Oncology, Södersjukhuset, Stockholm, Sweden.
Pharoah PDP; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.; Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
Adank MA; Family Cancer Clinic, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Hollestelle A; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Schmidt MK; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Hooning MJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.; Pokaż więcej
Corporate Authors:: NBCS Collaborators; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Research, Vestre Viken Hospital, Drammen, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Division of Surgery, Cancer and Transplantation Medicine, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.; Department of Oncology, Akershus University Hospital, Lørenskog, Norway.; Oslo Breast Cancer Research Consortium, Oslo University Hospital, Oslo, Norway.; Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway.; Department of Community Medicine, The Arctic University of Norway, Tromsø, Norway.; Core Facility for Biobanking, The Arctic University of Norway, Tromsø, Norway.
ABCTB Investigators; Australian Breast Cancer Tissue Bank, Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.
kConFab Investigators; Research Department, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Źródło:: Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (15), pp. 16142-16162. Date of Electronic Publication: 2023 Jul 03.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
MeSH Terms:: Breast Neoplasms*/genetics
Breast Neoplasms*/radiotherapy
Female ; Humans ; Checkpoint Kinase 2/genetics ; Genetic Predisposition to Disease ; Germ-Line Mutation ; Heterozygote ; Proportional Hazards Models

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting.
Autorzy:: Erber R; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Angeloni M; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Stöhr R; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Lux MP; Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Frauen Und Kinderklinik St. Louise, 33098 Paderborn, Germany.
Ulbrich-Gebauer D; Institute of Pathology Viersen, 41747 Viersen, Germany.
Pelz E; Institute of Pathology Viersen, 41747 Viersen, Germany.
Bankfalvi A; Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
Schmid KW; Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
Walter RFH; Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.; Ruhrlandklinik, West German Lung Center, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
Vetter M; Department of Gynecology, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.
Thomssen C; Department of Gynecology, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.
Mayr D; Institute of Pathology, Ludwig-Maximilian University (LMU), 80337 München, Germany.
Klauschen F; Institute of Pathology, Ludwig-Maximilian University (LMU), 80337 München, Germany.
Sinn P; Institute of Pathology, University Heidelberg, 69120 Heidelberg, Germany.
Sotlar K; Institute of Pathology, Ludwig-Maximilian University (LMU), 80337 München, Germany.; Institute of Pathology, Paracelsus Medical University Salzburg, A-5020 Salzburg, Austria.
Stering K; Institute of Pathology, Paracelsus Medical University Salzburg, A-5020 Salzburg, Austria.
Stenzinger A; Molekularpathologisches Zentrum, Pathologisches Institut, Universität Heidelberg, 69120 Heidelberg, Germany.
Wunderle M; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Department of Obstetrics & Gynecology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Fasching PA; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Department of Obstetrics & Gynecology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Beckmann MW; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Department of Obstetrics & Gynecology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Hoffmann O; Klinik für Frauenheilkunde und Geburtshilfe, Universität Duisburg-Essen, 45147 Essen, Germany.
Kimmig R; Klinik für Frauenheilkunde und Geburtshilfe, Universität Duisburg-Essen, 45147 Essen, Germany.
Harbeck N; Breast Center and CCC Munich, LMU University Hospital, Department of Obstetrics and Gynecology, 80337 Munich, Germany.
Wuerstlein R; Breast Center and CCC Munich, LMU University Hospital, Department of Obstetrics and Gynecology, 80337 Munich, Germany.
Ferrazzi F; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Hartmann A; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2022 Aug 05; Vol. 23 (15). Date of Electronic Publication: 2022 Aug 05.
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Breast Neoplasms*/metabolism
Oncologists*
Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Chemotherapy, Adjuvant ; Female ; Humans ; Immunohistochemistry ; Prospective Studies ; Receptor, ErbB-2/genetics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany.
Autorzy:: Huebner H; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Universitaetsstrasse 21-23, Erlangen, 91054, Germany.
Kurbacher CM; Gynecology I (Gynecologic Oncology), Gynecologic Center Bonn-Friedensplatz, Bonn, Germany.
Kuesters G; Merrimack Pharmaceuticals, Cambridge, MA, USA.
Hartkopf AD; Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
Lux MP; Klinik für Gynäkologie und Geburtshilfe Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Kooperatives Brustzentrum, Paderborn, Germany.
Huober J; Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
Volz B; Ansbach University of Applied Sciences, Ansbach, Germany.
Taran FA; Department of Gynecology, Zurich University Hospital, Zurich, Switzerland.
Overkamp F; Oncologianova GmbH, Recklinghausen, Germany.
Tesch H; Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany.
Häberle L; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Universitaetsstrasse 21-23, Erlangen, 91054, Germany.; Biostatistics Unit, Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany.
Lüftner D; Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumor Immunology, Charité University Hospital, Berlin, Germany.
Wallwiener M; Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.
Müller V; Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany.
Beckmann MW; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Universitaetsstrasse 21-23, Erlangen, 91054, Germany.
Belleville E; ClinSol GmbH & Co KG, Würzburg, Germany.
Ruebner M; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Universitaetsstrasse 21-23, Erlangen, 91054, Germany.
Untch M; Department of Gynecology and Obstetrics, Helios Clinics Berlin Buch, Berlin, Germany.
Fasching PA; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Universitaetsstrasse 21-23, Erlangen, 91054, Germany. .
Janni W; Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
Fehm TN; Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany.
Kolberg HC; Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany.
Wallwiener D; Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
Brucker SY; Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
Schneeweiss A; National Center for Tumor Diseases and Department of Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, Germany.
Ettl J; Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2020 Nov 11; Vol. 20 (1), pp. 1091. Date of Electronic Publication: 2020 Nov 11.
Typ publikacji:: Journal Article
MeSH Terms:: Patient Selection*
Antibodies, Monoclonal/*immunology
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Neoplasms/*pathology
Neuregulin-1/*metabolism
Pregnancy Complications, Neoplastic/*pathology
Registries/*statistics & numerical data
Adult ; Biomarkers, Tumor/immunology ; Biomarkers, Tumor/metabolism ; Case-Control Studies ; Clinical Trials as Topic ; Female ; Follow-Up Studies ; Germany ; Humans ; Middle Aged ; Neoplasms/drug therapy ; Neoplasms/immunology ; Neoplasms/metabolism ; Neuregulin-1/immunology ; Pregnancy ; Pregnancy Complications, Neoplastic/drug therapy ; Pregnancy Complications, Neoplastic/immunology ; Pregnancy Complications, Neoplastic/metabolism ; Prognosis ; Prospective Studies ; Survival Rate

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab.
Autorzy:: Michel LL; Department of Gynecology and Obstetrics, Heidelberg University Hospital, 69120 Heidelberg, Germany.; National Center for Tumor Diseases, Heidelberg University Hospital, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Hartkopf AD; Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany.
Fasching PA; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, 91054 Erlangen, Germany.
Kolberg HC; Department of Gynecology and Obstetrics, Marienhospital Bottrop, 46236 Bottrop, Germany.
Hadji P; Frankfurt Center for Bone Health, 60313 Frankfurt am Main, Germany.
Tesch H; Oncology Practice, Bethanien Hospital, 60389 Frankfurt am Main, Germany.
Häberle L; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, 91054 Erlangen, Germany.; Biostatistics Unit, Department of Gynecology and Obstetrics, Erlangen University Hospital, 91054 Erlangen, Germany.
Ettl J; Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany.
Lüftner D; Department of Hematology, Oncology and Tumor Immunology, Charité University Hospital, Campus Benjamin Franklin, 12203 Berlin, Germany.
Wallwiener M; Department of Gynecology and Obstetrics, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Müller V; Department of Gynecology, Hamburg-Eppendorf University Medical Center, 20246 Hamburg, Germany.
Beckmann MW; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, 91054 Erlangen, Germany.
Belleville E; ClinSol GmbH & Co KG, 97074 Würzburg, Germany.
Volz B; Ansbach University of Applied Sciences, 91522 Ansbach, Germany.
Huebner H; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, 91054 Erlangen, Germany.
Wimberger P; Department of Gynecology and Obstetrics, Carl Gustav Carus Faculty of Medicine and University Hospital, Technical University of Dresden, 01307 Dresden, Germany.; National Center for Tumor Diseases (NCT), Partner Site Dresden, Carl Gustav Carus Faculty of Medicine and University Hospital, Technical University of Dresden, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01328 Dresden, Germany.; German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Hielscher C; g.SUND Gynäkologie-Onkologisches Zentrum, 18435 Stralsund, Germany.
Mundhenke C; Department of Gynecology and Obstetrics, Klinik Hohe Warte, 95445 Bayreuth, Germany.
Kurbacher C; Department of Gynecology I (Gynecologic Oncology), Gynecologic Center Bonn-Friedensplatz, 53111 Bonn, Germany.
Wuerstlein R; Department of Gynecology and Obstetrics, Breast Center and CCC Munich, Munich University Hospital, 81377 Munich, Germany.
Untch M; Department of Gynecology and Obstetrics, Helios Clinics Berlin-Buch, 13125 Berlin, Germany.
Overkamp F; OncoConsult Overkamp GmbH, 10557 Berlin, Germany.
Huober J; Department of Gynecology and Obstetrics, Ulm University Hospital, 89075 Ulm, Germany.
Janni W; Department of Gynecology and Obstetrics, Ulm University Hospital, 89075 Ulm, Germany.
Taran FA; Department of Gynecology, Zurich University Hospital, 8091 Zurich, Switzerland.
Lux MP; Kooperatives Brustzentrum Paderborn, Department of Gynecology and Obstetrics, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, 33098 Paderborn, Germany.
Wallwiener D; Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany.
Brucker SY; Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany.
Schneeweiss A; National Center for Tumor Diseases, Heidelberg University Hospital, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Fehm TN; Department of Gynecology and Obstetrics, Düsseldorf University Hospital, 40225 Düsseldorf, Germany.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2020 Oct 17; Vol. 12 (10). Date of Electronic Publication: 2020 Oct 17.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women.
Autorzy:: Wunderle M; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Ruebner M; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Häberle L; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.; Biostatistics Unit, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Schwenke E; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Hack CC; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Bayer CM; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Koch MC; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Schwitulla J; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Schulz-Wendtland R; Institute of Diagnostic Radiology, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Kozieradzki I; Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, Canada.; Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.
Lux MP; Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Germany.
Beckmann MW; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Jud SM; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Penninger JM; Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, Canada.; Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.
Schneider MO; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Fasching PA; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2020 Mar 20; Vol. 10 (1), pp. 5171. Date of Electronic Publication: 2020 Mar 20.
Typ publikacji:: Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Breast/*metabolism
Osteoprotegerin/*metabolism
Pregnancy/*metabolism
RANK Ligand/*metabolism
Adult ; Breast/anatomy & histology ; Female ; Humans ; Prospective Studies ; Women's Health

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study.
Autorzy:: Matthies LM; Hospital for General Obstetrics and Gynecology, Gynecologic Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Taran FA; Department of Women's Health, University Hospital Tübingen, Tübingen, Germany.
Keilmann L; Hospital for General Obstetrics and Gynecology, Gynecologic Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Schneeweiss A; Hospital for General Obstetrics and Gynecology, Gynecologic Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Simoes E; Research Institute for Women's Health, Department of Women's Health, University Hospital Tübingen, Tübingen, Germany.
Hartkopf AD; Department of Women's Health, University Hospital Tübingen, Tübingen, Germany.
Sokolov AN; Research Institute for Women's Health, Department of Women's Health, University Hospital Tübingen, Tübingen, Germany.; Section of Midwifery Science, Institute for Health Sciences, University Hospital Tübingen, Tübingen, Germany.
Walter CB; Department of Women's Health, University Hospital Tübingen, Tübingen, Germany.
Sickenberger N; Hospital for General Obstetrics and Gynecology, Gynecologic Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Wallwiener S; Hospital for General Obstetrics and Gynecology, Gynecologic Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Feisst M; Institute for Medical Biometry and Informatics, University Hospital Heidelberg, Heidelberg, Germany.
Gass P; Department of Gynecology and Obstetrics, University Breast Center Franconia, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Erlangen, Germany.
Lux MP; Department of Gynecology and Obstetrics, University Breast Center Franconia, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Erlangen, Germany.
Schuetz F; Hospital for General Obstetrics and Gynecology, Gynecologic Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Fasching PA; Department of Gynecology and Obstetrics, University Breast Center Franconia, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Erlangen, Germany.
Sohn C; Hospital for General Obstetrics and Gynecology, Gynecologic Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Brucker SY; Research Institute for Women's Health, Department of Women's Health, University Hospital Tübingen, Tübingen, Germany.
Graf J; Research Institute for Women's Health, Department of Women's Health, University Hospital Tübingen, Tübingen, Germany.; Section of Midwifery Science, Institute for Health Sciences, University Hospital Tübingen, Tübingen, Germany.
Wallwiener M; Hospital for General Obstetrics and Gynecology, Gynecologic Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.; Pokaż więcej
Źródło:: Journal of medical Internet research [J Med Internet Res] 2019 Jan 22; Vol. 21 (1), pp. e10004. Date of Electronic Publication: 2019 Jan 22.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Patient Reported Outcome Measures*
Breast Neoplasms/*therapy
Psychometrics/*methods
Quality of Life/*psychology
Female ; Humans ; Reproducibility of Results ; Surveys and Questionnaires

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry.
Autorzy:: Lux MP; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University of Erlangen⁻Nuremberg, Universitätsstrasse 21⁻23, 91054 Erlangen, Germany. michael.lux@uk-erlangen.de.
Nabieva N; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University of Erlangen⁻Nuremberg, Universitätsstrasse 21⁻23, 91054 Erlangen, Germany. .
Hartkopf AD; Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany. .
Huober J; Department of Gynecology and Obstetrics, Ulm University Hospital, 89070 Ulm, Germany. .
Volz B; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University of Erlangen⁻Nuremberg, Universitätsstrasse 21⁻23, 91054 Erlangen, Germany. .
Taran FA; Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany. .
Overkamp F; Oncologianova GmbH, 45657 Recklinghausen, Germany. .
Kolberg HC; Marienhospital Bottrop, 46236 Bottrop, Germany. .
Hadji P; Department of Bone Oncology, Nordwest Hospital, 60488 Frankfurt, Germany. .
Tesch H; Oncology Practice at Bethanien Hospital Frankfurt; 60389 Frankfurt, Germany. .
Häberle L; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University of Erlangen⁻Nuremberg, Universitätsstrasse 21⁻23, 91054 Erlangen, Germany. .; Department of Gynecology and Obstetrics, Biostatistics Unit, Erlangen University Hospital, 91054 Erlangen, Germany. .
Ettl J; Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany. .
Lüftner D; Charité University Hospital, Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumour Immunology, 12203 Berlin, Germany. .
Wallwiener M; Department of Obstetrics and Gynecology, University of Heidelberg, 69120 Heidelberg, Germany. .
Müller V; Department of Gynecology, Hamburg-Eppendorf University Medical Center, 20246 Hamburg, Germany. .
Beckmann MW; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University of Erlangen⁻Nuremberg, Universitätsstrasse 21⁻23, 91054 Erlangen, Germany. .
Belleville E; ClinSol GmbH & Co KG, 97074 Würzburg, Germany. .
Wimberger P; Department of Gynecology and Obstetrics, Dresden University Hospital, 01307 Dresden, Germany. .
Hielscher C; gSUND Gynäkologie Kompetenzzentrum Stralsund, 18435 Stralsund, Germany. .
Geberth M; Gynäkologische Praxisklinik am Rosengarten, 68165 Mannheim, Germany. .
Abenhardt W; Medizinischen Versorgungszentrum Onkologie, Onkologie im Elisenhof, 80335 Munich, Germany. .
Kurbacher C; Department of Gynecology and Obstetrics, Medizinisches Zentrum Bonn Friedensplatz, 53111 Bonn, Germany. .
Wuerstlein R; Department of Gynecology and Obstetrics, Breast Center and Comprehensive Cancer Center Munich, Munich University Hospital, 80337 Munich, Germany. .
Thomssen C; Department of Gynecology, Martin Luther University of Halle-Wittenberg, 06120 Halle (Saale), Germany. .
Untch M; Department of Gynecology and Obstetrics, Helios Clinics Berlin Buch, 13125 Berlin, Germany. michael..
Fasching PA; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University of Erlangen⁻Nuremberg, Universitätsstrasse 21⁻23, 91054 Erlangen, Germany. .
Janni W; Department of Gynecology and Obstetrics, Ulm University Hospital, 89070 Ulm, Germany. .
Fehm TN; Department of Gynecology and Obstetrics, Düsseldorf University Hospital, 40225 Düsseldorf, Germany. .
Wallwiener D; Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany. .
Schneeweiss A; Department of Obstetrics and Gynecology, University of Heidelberg, 69120 Heidelberg, Germany. .; National Center for Tumor Diseases and Department of Gynecology and Obstetrics, Heidelberg University Hospital, 69120 Heidelberg, Germany. .
Brucker SY; Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany. .; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2018 Dec 21; Vol. 11 (1). Date of Electronic Publication: 2018 Dec 21.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.
Autorzy:: Gass P; Department of Gynecology and Obstetrics, Erlangen University Hospital, University Breast Center for Franconia, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany. .
Lux MP; Department of Gynecology and Obstetrics, Erlangen University Hospital, University Breast Center for Franconia, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.
Rauh C; Department of Gynecology and Obstetrics, Erlangen University Hospital, University Breast Center for Franconia, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.
Hein A; Department of Gynecology and Obstetrics, Erlangen University Hospital, University Breast Center for Franconia, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.
Bani MR; Department of Gynecology and Obstetrics, Erlangen University Hospital, University Breast Center for Franconia, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.
Fiessler C; Department of Medical Informatics, Biometry and Epidemiology, Friedrich Alexander University of Erlangen-Nuremberg, Waldstrasse 6, 91054, Erlangen, Germany.
Hartmann A; Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Krankenhausstrasse 8-10, 91054, Erlangen, Germany.
Häberle L; Department of Gynecology and Obstetrics, Erlangen University Hospital, University Breast Center for Franconia, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.; Biostatistics Unit, Department of Gynecology and Obstetrics, Erlangen University Hospital, Universitätsstrasse 21-23, 91054, Erlangen, Germany.
Pretscher J; Department of Gynecology and Obstetrics, Erlangen University Hospital, University Breast Center for Franconia, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.
Erber R; Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Krankenhausstrasse 8-10, 91054, Erlangen, Germany.
Wachter DL; Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Krankenhausstrasse 8-10, 91054, Erlangen, Germany.
Schulz-Wendtland R; Institute of Diagnostic Radiology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Maximiliansplatz 3, 91054, Erlangen, Germany.
Beckmann MW; Department of Gynecology and Obstetrics, Erlangen University Hospital, University Breast Center for Franconia, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.
Fasching PA; Department of Gynecology and Obstetrics, Erlangen University Hospital, University Breast Center for Franconia, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.
Wunderle M; Department of Gynecology and Obstetrics, Erlangen University Hospital, University Breast Center for Franconia, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2018 Oct 29; Vol. 18 (1), pp. 1051. Date of Electronic Publication: 2018 Oct 29.
Typ publikacji:: Journal Article
MeSH Terms:: Triple Negative Breast Neoplasms/*mortality
Triple Negative Breast Neoplasms/*pathology
Adult ; Aged ; Female ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Grading ; Neoplasm Staging ; Odds Ratio ; Prognosis ; Retrospective Studies ; Treatment Outcome ; Triple Negative Breast Neoplasms/therapy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
Autorzy:: Hoyer J; Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 10, 91054, Erlangen, Germany. .
Vasileiou G; Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 10, 91054, Erlangen, Germany.
Uebe S; Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 10, 91054, Erlangen, Germany.
Wunderle M; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Universitätsstr. 21-23, 91054, Erlangen, Germany.
Kraus C; Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 10, 91054, Erlangen, Germany.
Fasching PA; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Universitätsstr. 21-23, 91054, Erlangen, Germany.
Thiel CT; Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 10, 91054, Erlangen, Germany.
Hartmann A; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Krankenhausstr. 8-10, 91054, Erlangen, Germany.
Beckmann MW; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Universitätsstr. 21-23, 91054, Erlangen, Germany.
Lux MP; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Universitätsstr. 21-23, 91054, Erlangen, Germany.
Reis A; Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 10, 91054, Erlangen, Germany.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2018 Sep 26; Vol. 18 (1), pp. 926. Date of Electronic Publication: 2018 Sep 26.
Typ publikacji:: Journal Article
MeSH Terms:: Genetic Predisposition to Disease*
Germ-Line Mutation*
DNA Mutational Analysis/*methods
Triple Negative Breast Neoplasms/*genetics
Adult ; Aged ; Aged, 80 and over ; Cohort Studies ; Female ; High-Throughput Nucleotide Sequencing ; Humans ; Middle Aged ; Patient Selection ; Penetrance ; Sequence Analysis, DNA ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
Autorzy:: Huebner H; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Universitaetsstraße 21-23, 91054, Erlangen, Germany.
Fasching PA; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Universitaetsstraße 21-23, 91054, Erlangen, Germany.
Gumbrecht W; Siemens Healthcare GmbH, Günther-Scharowsky-Str.1, 91058, Erlangen, Germany.
Jud S; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Universitaetsstraße 21-23, 91054, Erlangen, Germany.
Rauh C; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Universitaetsstraße 21-23, 91054, Erlangen, Germany.
Matzas M; Siemens Healthcare GmbH, Günther-Scharowsky-Str.1, 91058, Erlangen, Germany.
Paulicka P; Siemens Healthcare GmbH, Günther-Scharowsky-Str.1, 91058, Erlangen, Germany.
Friedrich K; Siemens Healthcare GmbH, Günther-Scharowsky-Str.1, 91058, Erlangen, Germany.
Lux MP; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Universitaetsstraße 21-23, 91054, Erlangen, Germany.
Volz B; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Universitaetsstraße 21-23, 91054, Erlangen, Germany.
Gass P; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Universitaetsstraße 21-23, 91054, Erlangen, Germany.
Häberle L; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Universitaetsstraße 21-23, 91054, Erlangen, Germany.; Biostatistics Unit. Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Universitaetsstraße 21-23, 91054, Erlangen, Germany.
Meier-Stiegen F; Department of Gynecology and Obstetrics, Heinrich Heine University of Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.
Hartkopf A; Department of Gynecology and Obstetrics, University Hospital Tuebingen, Calwerstraße 7, 72076, Tuebingen, Germany.
Neubauer H; Department of Gynecology and Obstetrics, Heinrich Heine University of Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.
Almstedt K; Department of Obstetrics and Gynecology, Johannes Gutenberg University, Langenbeckstrasse 1, 55131, Mainz, Germany.
Beckmann MW; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Universitaetsstraße 21-23, 91054, Erlangen, Germany.
Fehm TN; Department of Gynecology and Obstetrics, Heinrich Heine University of Düsseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.
Ruebner M; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Universitaetsstraße 21-23, 91054, Erlangen, Germany. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2018 Feb 20; Vol. 18 (1), pp. 204. Date of Electronic Publication: 2018 Feb 20.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Flow Cytometry*
Breast Neoplasms/*diagnosis
Breast Neoplasms/*mortality
Filtration/*methods
Neoplastic Cells, Circulating/*pathology
Aged ; Biomarkers, Tumor ; Breast Neoplasms/metabolism ; Epithelial Cell Adhesion Molecule/metabolism ; Female ; Fluorescent Antibody Technique ; Humans ; Immunomagnetic Separation ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Neoplastic Cells, Circulating/metabolism ; Proportional Hazards Models ; Prospective Studies ; Reproducibility of Results

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Implementation of a Systematic Literature Search Strategy in a National Breast Cancer Guideline: The Relevance of Systemic Therapy in Lymph Node Recurrent Disease.
Autorzy:: Stüber TN
Stangl S
Jackisch C
Janni W
Brucker SY
Hartkopf A
Gerber B
Budach W
Lux MP
Wöckel A; Pokaż więcej
Źródło:: Oncology research and treatment [Oncol Res Treat] 2018; Vol. 41 (9), pp. 554-559. Date of Electronic Publication: 2018 Aug 17.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Practice Guidelines as Topic*
Review Literature as Topic*
Antineoplastic Agents/*therapeutic use
Breast Neoplasms/*therapy
Neoplasm Recurrence, Local/*therapy
Breast Neoplasms/pathology ; Chemotherapy, Adjuvant/methods ; Chemotherapy, Adjuvant/standards ; Consensus ; Female ; Germany ; Humans ; Lymph Nodes/pathology ; Lymphatic Metastasis ; Mastectomy ; Medical Oncology/standards ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/pathology ; Observational Studies as Topic ; Radiotherapy, Adjuvant/methods ; Radiotherapy, Adjuvant/standards ; Randomized Controlled Trials as Topic

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial.
Autorzy:: Wallwiener M; Gynecologic Oncology, National Center for Tumor Diseases, Hospital for General Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany.
Matthies L; Gynecologic Oncology, National Center for Tumor Diseases, Hospital for General Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany.
Simoes E; Research Institute for Women's Health, Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany.
Keilmann L; Gynecologic Oncology, National Center for Tumor Diseases, Hospital for General Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany.
Hartkopf AD; Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany.
Sokolov AN; Research Institute for Women's Health, Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany.
Walter CB; Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany.
Sickenberger N; Gynecologic Oncology, National Center for Tumor Diseases, Hospital for General Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany.
Wallwiener S; Gynecologic Oncology, National Center for Tumor Diseases, Hospital for General Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany.
Feisst M; Institute for Medical Biometry and Informatics, University Hospital Heidelberg, Heidelberg, Germany.
Gass P; Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany.
Fasching PA; Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany.
Lux MP; Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany.
Wallwiener D; Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany.
Taran FA; Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany.
Rom J; Gynecologic Oncology, National Center for Tumor Diseases, Hospital for General Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany.
Schneeweiss A; Gynecologic Oncology, National Center for Tumor Diseases, Hospital for General Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany.
Graf J; Research Institute for Women's Health, Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany.
Brucker SY; Research Institute for Women's Health, Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany.; Pokaż więcej
Źródło:: Journal of medical Internet research [J Med Internet Res] 2017 Sep 14; Vol. 19 (9), pp. e322. Date of Electronic Publication: 2017 Sep 14.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Breast Neoplasms/*epidemiology
Quality of Life/*psychology
Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/psychology ; Female ; Humans ; Middle Aged ; Prospective Studies ; Reproducibility of Results ; Surveys and Questionnaires

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases.
Autorzy:: Lux MP; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University, Universitätsstrasse 21-23, 91054, Erlangen, Germany. michael.lux@uk-erlangen.de.
Hildebrandt T; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University, Universitätsstrasse 21-23, 91054, Erlangen, Germany. .
Knetzger SM; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University, Universitätsstrasse 21-23, 91054, Erlangen, Germany. .
Schrauder MG; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University, Universitätsstrasse 21-23, 91054, Erlangen, Germany. michael..
Jud SM; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University, Universitätsstrasse 21-23, 91054, Erlangen, Germany. .
Hein A; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University, Universitätsstrasse 21-23, 91054, Erlangen, Germany. .
Rauh C; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University, Universitätsstrasse 21-23, 91054, Erlangen, Germany. .
Fasching PA; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University, Universitätsstrasse 21-23, 91054, Erlangen, Germany. .
Beckmann MW; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University, Universitätsstrasse 21-23, 91054, Erlangen, Germany. .
Thiel FC; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University, Universitätsstrasse 21-23, 91054, Erlangen, Germany. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2015 Aug 14; Vol. 15, pp. 587. Date of Electronic Publication: 2015 Aug 14.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Health Knowledge, Attitudes, Practice*
Breast Neoplasms/*epidemiology
Breast Neoplasms/*psychology
Clinical Studies as Topic/*psychology
Genital Diseases, Female/*epidemiology
Genital Diseases, Female/*psychology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biomedical Research ; Cross-Sectional Studies ; Female ; Humans ; Middle Aged ; Surveys and Questionnaires ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.
Autorzy:: Fasching PA; University Breast Center, Department of Gynecology and Obstetrics, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. .
Jud SM
Hauschild M
Kümmel S
Schütte M
Warm M
Hanf V
Grab D
Krocker J
Stickeler E
Kreienberg R
Müller T
Kühn T
Wolf C
Kahlert S
Paepke S
Berghorn M
Muth M
Baier M
Wackwitz B
Schulz-Wendtland R
Beckmann MW
Lux MP; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2014 Feb 05; Vol. 14, pp. 66. Date of Electronic Publication: 2014 Feb 05.
Typ publikacji:: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Breast Neoplasms/*diagnosis
Breast Neoplasms/*drug therapy
Neoadjuvant Therapy/*methods
Nitriles/*administration & dosage
Triazoles/*administration & dosage
Aged ; Aged, 80 and over ; Breast Neoplasms/epidemiology ; Diphosphonates/administration & dosage ; Female ; Humans ; Imidazoles/administration & dosage ; Letrozole ; Middle Aged ; Prospective Studies ; Zoledronic Acid

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Best supportive care from the conservative/non-surgical perspective and its costs in the treatment of patients with advanced medullary thyroid cancer: results of a Delphi panel.
Autorzy:: Kreissl MC; Department of Nuclear Medicine, University Hospital of Wuerzburg, Germany.
Jacob C
Führer D
Karges W
Luster M
Lux MP
Mann K
Mittendorf T
Schott M
Spitzweg C
Schmoll HJ; Pokaż więcej
Źródło:: Oncology research and treatment [Oncol Res Treat] 2014; Vol. 37 (6), pp. 316-22. Date of Electronic Publication: 2014 May 12.
Typ publikacji:: Journal Article
MeSH Terms:: Quality of Life*
Health Care Costs/*statistics & numerical data
Palliative Care/*economics
Palliative Care/*methods
Thyroid Neoplasms/*economics
Thyroid Neoplasms/*therapy
Carcinoma, Neuroendocrine ; Delphi Technique ; Germany/epidemiology ; Humans ; Palliative Care/statistics & numerical data ; Prevalence ; Risk Factors ; Survival Rate ; Thyroid Neoplasms/mortality ; Thyroidectomy/economics ; Treatment Outcome
SCR Disease Name:: Thyroid cancer, medullary

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients.
Autorzy:: Hein A; Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Bayer CM; Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Schrauder MG; Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Häberle L; Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Heusinger K; Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Strick R; Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Ruebner M; Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Lux MP; Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Renner SP; Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Schulz-Wendtland R; Institute of Diagnostic Radiology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Ekici AB; Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Hartmann A; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Beckmann MW; Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Fasching PA; Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.; Pokaż więcej
Źródło:: BioMed research international [Biomed Res Int] 2014; Vol. 2014, pp. 842452. Date of Electronic Publication: 2014 Mar 05.
Typ publikacji:: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Bone Neoplasms*/genetics
Bone Neoplasms*/mortality
Bone Neoplasms*/pathology
Bone Neoplasms*/secondary
Breast Neoplasms*/genetics
Breast Neoplasms*/mortality
Breast Neoplasms*/pathology
Polymorphism, Single Nucleotide*
RANK Ligand/*genetics
Receptor Activator of Nuclear Factor-kappa B/*genetics
Aged ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Middle Aged ; Neoplasm Metastasis ; Retrospective Studies ; Survival Rate